Favorable safety profile is a substantial benefit in the treatment of chronic diseases that require long-term dosing PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline...
Phase 2 Clinical Trials to Begin subject to FDA IND Approval HOUSTON, March 3, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel...
− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd)...
WASHINGTON – A U.S. biomedical firm has announced it will begin additional clinical trials of remdesivir, so far the most promising potential drug for coronavirus, with clinical trials involving about 1,000 patients starting in March. In a sign that the drug,...
Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib provided statistically significant improvement in...
Email
Text